Exphar is registered with the CBE as active in: Groothandel in farmaceutische producten. Public Limited, started on 27 August 1981, 1 establishment.

What is the address of Exphar?

The registered office of Exphar is located at Avenue Thomas Edison 105, 1402 Nivelles.

Is Exphar still active?

Yes. According to the CBE (29 October 2026) Exphar is active, legal situation “Normale toestand”, started on 27 August 1981.

Is Exphar registered on Peppol?

Yes, Exphar is registered on the Peppol network with ID 0208:0421802718.

What is the enterprise number of Exphar?

The enterprise number of Exphar is BE0421802718.

When was Exphar founded?

Exphar was founded on 27 August 1981.

Who are the directors of Exphar?

According to the 2025 annual accounts, the directors of Exphar are: Ricardo ALVES MARTINS, LHVK SRL, Koen SMESSAERT, Jean-Olivier COLLINET.

Is Exphar a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 August 1981; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did Exphar make in 2025?

Exphar posted a profit after taxes of € 868,458 in financial year 2025.

What is the revenue of Exphar?

In its most recent annual accounts (2025), Exphar reported revenue of € 22,881,746.

How much does an employee at Exphar earn?

The average wage cost per full-time employee at Exphar was € 88,200 in 2025: staff costs of € 2.4 million for 27 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Exphar have?

According to the 2025 annual accounts, Exphar has 27 full-time equivalents (FTE).

Exphar (Public Limited) - Nivelles - BE0421802718

Dossier Exphar, printed on 29 October 2026 from databakkes.be/en/0421802718/exphar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 49 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Exphar from Nivelles, company number BE0421802718, closed financial year 2025 with a result of € 868,458 after tax. For that financial year Exphar recorded revenue of € 22.9 million and equity of € 5.5 million. Compared with financial year 2024, the result moved from € 396,568 to € 868,458. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 14, 2026.

What it is worth Growing

€ 5.5 million

▲ 18% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 868,458

▲ 119% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.8 million

▼ 11% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 4.1 million.

People and assets in 2025

Full-time equivalents

▲ 2.9 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 4.9 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 2.4 million

▲ 13% vs 2024

€ 88,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 133,351

▼ 25% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 4.2 million

▼ 15% vs 2024

€ 510,764 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 472,281

▼ 60% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 9 days on average.

Taxes and wages

€ 691,290

▲ 38% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 21,053,933 Revenue 2022: € 21,053,933 First fiscal year in the series	€ 20,920,083 Revenue 2023: € 20,920,083 ▼ 1% vs 2022 (€ 21,053,933) Unfavourable step	€ 22,408,597 Revenue 2024: € 22,408,597 ▲ 7% vs 2023 (€ 20,920,083) Favourable step	€ 22,881,746 Revenue 2025: € 22,881,746 ▲ 2% vs 2024 (€ 22,408,597) Favourable step	▲ 2%
Profit after taxes	€ 987,001 Profit after taxes 2022: € 987,001 First fiscal year in the series	€ 1,154,073 Profit after taxes 2023: € 1,154,073 ▲ 17% vs 2022 (€ 987,001) Favourable step	€ 396,568 Profit after taxes 2024: € 396,568 ▼ 66% vs 2023 (€ 1,154,073) Unfavourable step	€ 868,458 Profit after taxes 2025: € 868,458 ▲ 119% vs 2024 (€ 396,568) Favourable step	▲ 119%
Equity	€ 6,517,090 Equity 2022: € 6,517,090 First fiscal year in the series	€ 4,257,614 Equity 2023: € 4,257,614 ▼ 35% vs 2022 (€ 6,517,090) Unfavourable step	€ 4,699,532 Equity 2024: € 4,699,532 ▲ 10% vs 2023 (€ 4,257,614) Favourable step	€ 5,541,340 Equity 2025: € 5,541,340 ▲ 18% vs 2024 (€ 4,699,532) Favourable step	▲ 18%
Total debts	€ 9,862,189 Total debts 2022: € 9,862,189 First fiscal year in the series	€ 13,073,864 Total debts 2023: € 13,073,864 ▲ 33% vs 2022 (€ 9,862,189) Unfavourable step	€ 11,373,461 Total debts 2024: € 11,373,461 ▼ 13% vs 2023 (€ 13,073,864) Favourable step	€ 8,503,980 Total debts 2025: € 8,503,980 ▼ 25% vs 2024 (€ 11,373,461) Favourable step	▼ 25%
Cash	€ 473,279 Cash 2022: € 473,279 First fiscal year in the series	€ 1,033,286 Cash 2023: € 1,033,286 ▲ 118% vs 2022 (€ 473,279) Favourable step	€ 1,963,457 Cash 2024: € 1,963,457 ▲ 90% vs 2023 (€ 1,033,286) Favourable step	€ 1,754,257 Cash 2025: € 1,754,257 ▼ 11% vs 2024 (€ 1,963,457) Unfavourable step	▼ 11%
Land & buildings	€ 6,469,418 Land & buildings 2022: € 6,469,418 First fiscal year in the series	€ 6,359,537 Land & buildings 2023: € 6,359,537 ▼ 2% vs 2022 (€ 6,469,418) Unchanged	€ 5,988,990 Land & buildings 2024: € 5,988,990 ▼ 6% vs 2023 (€ 6,359,537) Unchanged	€ 5,610,516 Land & buildings 2025: € 5,610,516 ▼ 6% vs 2024 (€ 5,988,990) Unchanged	▼ 6%
Retained profit	€ 5,216,770 Retained profit 2022: € 5,216,770 First fiscal year in the series	€ 2,870,844 Retained profit 2023: € 2,870,844 ▼ 45% vs 2022 (€ 5,216,770) Unfavourable step	€ 3,267,412 Retained profit 2024: € 3,267,412 ▲ 14% vs 2023 (€ 2,870,844) Favourable step	€ 4,135,870 Retained profit 2025: € 4,135,870 ▲ 27% vs 2024 (€ 3,267,412) Favourable step	▲ 27%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 3,500,000 Dividend 2023: € 3,500,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 3,500,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 5,147,371 Bank debt 2022: € 5,147,371 First fiscal year in the series	€ 3,497,103 Bank debt 2023: € 3,497,103 ▼ 32% vs 2022 (€ 5,147,371) Favourable step	€ 4,945,393 Bank debt 2024: € 4,945,393 ▲ 41% vs 2023 (€ 3,497,103) Unfavourable step	€ 4,222,855 Bank debt 2025: € 4,222,855 ▼ 15% vs 2024 (€ 4,945,393) Favourable step	▼ 15%
Balance sheet total	€ 16,696,294 Balance sheet total 2022: € 16,696,294 First fiscal year in the series	€ 17,438,741 Balance sheet total 2023: € 17,438,741 ▲ 4% vs 2022 (€ 16,696,294) Unchanged	€ 16,170,505 Balance sheet total 2024: € 16,170,505 ▼ 7% vs 2023 (€ 17,438,741) Unchanged	€ 14,133,080 Balance sheet total 2025: € 14,133,080 ▼ 13% vs 2024 (€ 16,170,505) Unchanged	▼ 13%
Employees (FTE)	15.5 Employees (FTE) 2022: 15.5 First fiscal year in the series	19 Employees (FTE) 2023: 19 ▲ 3.5 vs 2022 (15.5) Unchanged	24.1 Employees (FTE) 2024: 24.1 ▲ 5.1 vs 2023 (19) Unchanged	27 Employees (FTE) 2025: 27 ▲ 2.9 vs 2024 (24.1) Unchanged	▲ 2.9

Key figures of Exphar, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Exphar?

What happened at Exphar in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 LHVK SRL stepped down as director. NBB
2028 Ricardo ALVES MARTINS stepped down as director. NBB
2028 Koen SMESSAERT stepped down as director. NBB
2027 Jean-Olivier COLLINET stepped down as director. NBB
Jul 14, 2026 New annual accounts for financial year 2025: profit of € 868,458 (▲ 119% vs 2024). Source: NBB ↗
2026 Ricardo ALVES MARTINS became a director. NBB
2026 Koen SMESSAERT became a director. NBB
2025 Jean-Olivier COLLINET became a director. NBB

In short

From € 987,001 profit in 2022 to € 868,458 profit in 2025.

Paid € 1.3 million in corporate taxes since 2022.

Best year ever: 2023, with € 1.2 million profit.

Paid out € 3.5 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

H & H PHARMACEUTICALS 93.7%

The stake of H & H PHARMACEUTICALS comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Exphar

EXPHARLAB LIMITED 100%

H&H Pharma LTD 100%

GRACURE 5.1%

The shares are held by H & H PHARMACEUTICALS (93.7%). It owns 100% of EXPHARLAB LIMITED, 100% of H&H Pharma LTD and 5.1% of GRACURE itself.

Directors

According to the 2025 annual accounts

Ricardo ALVES MARTINS

Director

since 2026 · until 2028

LHVK SRL

Director · represented by Laurent HAVERBEKE

since 2024 · until 2028

Koen SMESSAERT

Director

since 2026 · until 2028

Jean-Olivier COLLINET

Director

Also active at: GROUPE ONE, JOBYOURSELF COOP, BATICREA, CREO, jobyourself in brussels

since 2025 · until 2027

Shareholders

H & H PHARMACEUTICALS

93.7%

Participations

EXPHARLAB LIMITED

100%

H&H Pharma LTD

100%

GRACURE

5.1%

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue Thomas Edison 105

1402 Nivelles

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

H & H PHARMACEUTICALS same network

€ 1.7 million revenue · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0421.802.718

VAT number

BE 0421.802.718

Registered office

Avenue Thomas Edison 105, 1402 Nivelles

Names & denominations

Exphar

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

27 August 1981

Peppol

Active · Active since 1 Jan 2001

Activities · NACE

Groothandel in farmaceutische producten

Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

Exphar

Warning lights

Financials

What happened to Exphar?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions